ArticleNature chemical biology2014
VMAT2 identified as a regulator of late-stage β-cell differentiation.
Article in Nature chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 61 citations in OpenAlex.
- Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.Molecular imaging and biology · 2016Trial
- Pancreatic stem cells originate during the pancreatic progenitor developmental stage.Frontiers in cell and developmental biology · 2025Article
- Human expandable pancreatic progenitor-derived β cells ameliorate diabetes.Science advances · 2022Article
- Phenotypic technologies in stem cell biology.Cell chemical biology · 2021Review
- Recent progress in pancreatic islet cell therapy.Inflammation and regeneration · 2021Review
- VMAT2 Safeguards β-Cells Against Dopamine Cytotoxicity Under High-Fat Diet-Induced Stress.Diabetes · 2020Article
- Klf6 protects β-cells against insulin resistance-induced dedifferentiation.Molecular metabolism · 2020Article
- A novel optical tracer for VMAT2 applied to live cell measurements of vesicle maturation in cultured human β-cells.Scientific reports · 2019Article
- Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging.Diabetologia · 2018Article
- iPSC technology-based regenerative therapy for diabetes.Journal of diabetes investigation · 2018Review
- Adrenergic receptor agonists induce the differentiation of pluripotent stem cell-derived hepatoblasts into hepatocyte-like cells.Scientific reports · 2017Article
- Chemical reprogramming of mouse embryonic and adult fibroblast into endoderm lineage.The Journal of biological chemistry · 2017Article
- PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration.Stem cell research & therapy · 2017Review
- Beta-cell replacement strategies for diabetes.Journal of diabetes investigation · 2017Review
- An inhibitor of fibroblast growth factor receptor-1 (FGFR1) promotes late-stage terminal differentiation from NGN3+ pancreatic endocrine progenitors.Scientific reports · 2016Article
- Development of an optimized 5-stage protocol for the in vitro preparation of insulin-secreting cells from mouse ES cells.Cytotechnology · 2016Article
- Dopamine D2 Receptor-Mediated Regulation of Pancreatic β Cell Mass.Stem cell reports · 2016Article
- Late stage definitive endodermal differentiation can be defined by Daf1 expression.BMC developmental biology · 2016Article
- Insulin-secreting β cells require a post-genomic concept.World journal of diabetes · 2016Review
- Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.Transplantation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell replacement therapy for diabetes mellitus requires cost-effective generation of high-quality, insulin-producing, pancreatic β cells from pluripotent stem cells. Development of this technique has been hampered by a lack of knowledge of the molecular mechanisms underlying β-cell differentiation. The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors. VMAT2-controlled monoamines, such as dopamine, histamine and serotonin, negatively regulated β-cell differentiation. Reserpine or TBZ acted additively with dibutyryl adenosine 3',5'-cyclic AMP, a cell-permeable cAMP analog, to potentiate differentiation of embryonic stem (ES) cells into β cells that exhibited glucose-stimulated insulin secretion. When ES cell-derived β cells were transplanted into AKITA diabetic mice, the cells reversed hyperglycemia. Our protocol provides a basis for the understanding of β-cell differentiation and its application to a cost-effective production of functional β cells for cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.